Insights

Why is the BARD1 Life Sciences (ASX:BD1) share price rocketing 78%?

The BARD1 Life Sciences share price is up an eye-popping 78% in early afternoon trading. We look at what’s driving ASX investor interest.
The post Why is the BARD1 Life Sciences (ASX:BD1) share price rocketing 78%? appeared first on The Motley Fool Australia. –

woman in lab coat conducting testing representing mesoblast share price

The BARD1 Life Sciences Ltd (ASX: BD1) share price is up an eye-popping 66% at the time of writing. That’s down a bit from gains of more than 87% in early morning trade.

Investor interest appears to be driven by the company’s positive announcement on its ovarian cancer test. Let’s take a closer look at the announcement and what it means for the BARD1 share price.

What did BARD1 report on its cancer test?

BARD1 released a report to the ASX this morning stating that it’s SubB2M technology is able to detect all stages of ovarian cancer.  The data was collected from Griffith University’s Institute of Glycomics. It indicates the technology is able to do this with 100% specificity and 100% sensitivity.

SubB2M is a protein that binds to a sugar molecule called Neu5Gc. This protein is present in a range of cancers. The company reported that researchers from the University of Adelaide and Griffith University have proven its ability to detect Neu5Gc in cancer patients’ bloodstreams.

BARD1 holds the exclusive worldwide license for the use of SubB2M to detect any cancer.

Dr. Lucy Shewell from Griffith University’s Institute for Glycomics concluded that detection of Neu5Gc-glycans using SubB2M can potentially be used as a diagnostic marker to detect early-stage ovarian cancer. She said it may also be a useful tool to monitor disease progression in late-stage cancer.

Comments from the CEO

Addressing the positive results, BARD1’s CEO, Dr. Leearne Hinch, said:

The company is focused on early detection of cancer and our SubB2M technology provides the potential for developing tests for monitoring and detection of multiple cancers. We will continue to collaborate with Griffith University to develop and validate commercial assays for monitoring treatment response and recurrence in ovarian cancer patients to improve health outcomes for this critical unmet medical need.

The company also stated that ovarian cancer remains the leading cause of gynaecological cancer deaths worldwide. This statement highlights the potential benefits of its SubB2M test. In 2018 there were 185,000 deaths from ovarian cancer. Ovarian cancer often progresses to a late-stage before diagnosis. This means the current 5-year survival rate is only 46%.

BARD1 share price snapshot

The BARD1 share price has a lengthy history of volatility, even without the 49% share price crash during last autumn’s COVID-driven market rout. With today’s intraday gains factored in, the BARD1 share price is up 88% in 2021.

By comparison, the All Ordinaries Index (ASX: XAO) is up just over 2%.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why is the BARD1 Life Sciences (ASX:BD1) share price rocketing 78%? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!